Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00327834 · ClinicalTrials.gov registry record · Phase 4

Atomoxetine in the Treatment of Binge Eating Disorder

A Phase 4 study of Binge-Eating Disorder, sponsored by Lindner Center of HOPE.

Completed
Registry status
Phase 4
Development phase
1
Study location

NCT00327834: Completed Phase 4 study of Binge-Eating Disorder, sponsored by Lindner Center of HOPE.

NCT00327834 is a Phase 4 study of Binge-Eating Disorder that has completed, run by Lindner Center of HOPE. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00327834, a Phase 4 study of Binge-Eating Disorder, has completed, sponsored by Lindner Center of HOPE.

COMPLETED
Registry status
Phase 4
Development phase
1
Study location

Study Summary

The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Conditions Studied

Interventions

  • DRUG atomoxetine

Study Locations (1)

Ohio

  • University of Cincinnati Medical Center - Cincinnati

Trial Details

FieldValue
Start Date 2006-05
Est. Completion 2007-03
Phase Phase 4
Lindner Center of HOPE

23 total trials

What the finished NCT00327834 record still lists

NCT00327834 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Binge-Eating Disorder appearing as the primary indexed condition, and to 1 intervention - of which atomoxetine is the first listed.

NCT00327834 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT00327834 about?

NCT00327834 is a clinical study titled "Atomoxetine in the Treatment of Binge Eating Disorder". The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

What is the current status of trial NCT00327834?

This trial is currently completed. It is a Phase 4 study. The study started on 2006-05. Estimated completion is 2007-03.

What conditions does trial NCT00327834 study?

This clinical trial studies the following conditions: Binge-Eating Disorder.

What interventions are being tested in trial NCT00327834?

The interventions under investigation include: atomoxetine (DRUG).

Who is sponsoring clinical trial NCT00327834?

This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00327834 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00327834, the US trial registry maintained by the National Library of Medicine. NCT00327834 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.